Biotest AG (BTTAY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biotest AG (BTTAY) with AI Score 48/100 (Weak). Biotest Aktiengesellschaft is a German biopharmaceutical company specializing in the development, manufacture, and sale of biological and biotechnological products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Biotest AG (BTTAY) Healthcare & Pipeline Overview
Biotest Aktiengesellschaft, a German biopharmaceutical company, develops and markets biological and biotechnological products, focusing on clinical immunology, haematology, and intensive care. With a global presence and a diverse product portfolio, Biotest addresses critical needs in specialized therapeutic areas, operating as a subsidiary of Grifols Biotest Holdings GmbH.
Investment Thesis
Biotest Aktiengesellschaft, with a market capitalization of $1.60 billion, presents a complex investment case. The company's focus on specialized therapeutic areas like immunology and haematology offers growth potential, particularly through its licensing agreement with Grifols. However, a negative profit margin of -3.9% and ROE of -4.7% raise concerns about profitability. The high debt-to-equity ratio of 131.22 indicates significant leverage. Upcoming catalysts include potential expansion of its product portfolio and increased market penetration through its partnership with Grifols. Potential risks include ongoing operational losses and the competitive nature of the biopharmaceutical industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $1.60B reflects Biotest's valuation in the biopharmaceutical sector.
- Negative Profit Margin of -3.9% indicates ongoing challenges in achieving profitability.
- Gross Margin of 23.2% suggests potential for improvement in production and sales efficiency.
- Debt-to-Equity Ratio of 131.22 indicates a highly leveraged capital structure.
- Free Cash Flow of $-0.00B reflects the company's current inability to generate positive cash flow.
Competitors & Peers
Strengths
- Specialized product portfolio in immunology and haematology.
- Established presence in Germany.
- Partnership with Grifols for manufacturing and marketing.
- Expertise in biological and biotechnological pharmaceutical products.
Weaknesses
- Negative profit margin and ROE.
- High debt-to-equity ratio.
- Dependence on a limited number of key products.
- Limited geographic diversification.
Catalysts
- Ongoing: Potential for increased revenue through the Grifols partnership.
- Upcoming: Expansion of product portfolio through R&D initiatives.
- Upcoming: Geographic expansion into emerging markets.
- Ongoing: Development of new therapies for clinical immunology and haematology.
Risks
- Ongoing: Negative profit margin and ROE.
- Ongoing: High debt-to-equity ratio.
- Potential: Intense competition from major pharmaceutical companies.
- Potential: Stringent regulatory requirements and approval processes.
- Potential: Limited liquidity due to OTC market trading.
Growth Opportunities
- Expansion of Product Portfolio: Biotest has the opportunity to expand its product portfolio through internal research and development, as well as strategic acquisitions or licensing agreements. Focusing on innovative therapies in clinical immunology, haematology, and intensive care medicine can drive revenue growth. The global market for immunomodulatory drugs is projected to reach $124.7 billion by 2027, presenting a significant opportunity for Biotest. Timeline: Ongoing.
- Increased Market Penetration through Grifols Partnership: The technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin provides Biotest with access to Grifols' global distribution network. This partnership can significantly increase market penetration and sales volume for these key products. The global market for plasma-derived therapies is expected to grow, driven by increasing demand for specialized treatments. Timeline: Ongoing.
- Geographic Expansion: Biotest can pursue geographic expansion into new markets, particularly in emerging economies with growing healthcare expenditures. Expanding its presence in regions with unmet medical needs can drive revenue growth and diversify its revenue streams. The emerging markets pharmaceutical sector is expected to grow significantly, offering substantial opportunities for Biotest. Timeline: 3-5 years.
- Strategic Acquisitions: Biotest could pursue strategic acquisitions of smaller biotechnology companies with complementary technologies or product pipelines. Acquiring innovative therapies or technologies can enhance Biotest's product portfolio and strengthen its competitive position. The market for mergers and acquisitions in the biopharmaceutical industry remains active, providing opportunities for strategic growth. Timeline: 2-3 years.
- Development of Biosimilars: Biotest can invest in the development of biosimilars, which are follow-on versions of existing biologic drugs. Biosimilars offer a lower-cost alternative to branded biologics and can capture a significant share of the market. The global biosimilars market is projected to reach $35.7 billion by 2025, presenting a substantial opportunity for Biotest. Timeline: 5+ years.
Opportunities
- Expansion of product portfolio through R&D and acquisitions.
- Increased market penetration through Grifols partnership.
- Geographic expansion into emerging markets.
- Development of biosimilars.
Threats
- Intense competition from major pharmaceutical companies.
- Stringent regulatory requirements and approval processes.
- Risk of product liability claims.
- Potential for generic erosion of key products.
Competitive Advantages
- Specialized product portfolio in niche therapeutic areas.
- Technology transfer and licensing agreement with Grifols, S.A.
- Established presence in the German biopharmaceutical market.
- Expertise in developing and manufacturing biological pharmaceutical products.
About BTTAY
Biotest Aktiengesellschaft, founded in 1946 and headquartered in Dreieich, Germany, is a biopharmaceutical company specializing in biological and biotechnological pharmaceutical products. Originally named Biotest Serum-Institut GmbH, the company changed its name in 1986 to Biotest Aktiengesellschaft. The company focuses on the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its product portfolio includes treatments for haemophilia A and B, cytomegalovirus infection, hepatitis B, primary and secondary antibody deficiency syndromes, autoimmune diseases, varicella zoster virus infections, and hepatitis B reinfection following liver transplantation. Key products include Haemoctin SDH and Vihuma for haemophilia A, Haemonine for haemophilia B, Cytotect CP biotest for cytomegalovirus, Fovepta and Hepatect CP for hepatitis B, and Intratect and Yimmugo for antibody deficiency syndromes and autoimmune diseases. Additionally, Biotest offers Albiomin and Biseco for blood volume restoration, Cofact for coagulation factor deficiency, Fibrinogen for fibrinogen deficiency, Trimodulin for community-acquired pneumonia, and Pentaglobin for bacterial infections. Biotest has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin, expanding its global reach and market presence. As a subsidiary of Grifols Biotest Holdings GmbH, Biotest leverages its parent company's resources and expertise to further its research, development, and commercialization efforts.
What They Do
- Develops biological pharmaceutical products.
- Manufactures biological pharmaceutical products.
- Sells biological pharmaceutical products in Germany and internationally.
- Specializes in clinical immunology therapies.
- Focuses on haematology treatments.
- Provides intensive care medicine solutions.
- Offers therapies for haemophilia A and B.
- Develops treatments for autoimmune diseases.
Business Model
- Develops and manufactures biological and biotechnological pharmaceutical products.
- Sells products directly and through partnerships in Germany and internationally.
- Generates revenue through the sale of specialized therapies for clinical immunology, haematology, and intensive care medicine.
- Utilizes technology transfer and licensing agreements to expand market reach.
Industry Context
Biotest Aktiengesellschaft operates in the biopharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases. Biotest's focus on specialized therapeutic areas like immunology and haematology positions it within niche segments of this market. Competitors include major pharmaceutical companies and specialized biotech firms. The company's partnership with Grifols provides a competitive advantage through expanded market access and shared resources.
Key Customers
- Hospitals and clinics requiring specialized therapies.
- Patients with haemophilia A and B.
- Individuals with cytomegalovirus infection.
- Patients with hepatitis B.
- Individuals with primary and secondary antibody deficiency syndromes.
Financials
Chart & Info
Biotest AG (BTTAY) stock price: Price data unavailable
Latest News
No recent news available for BTTAY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BTTAY.
Price Targets
Wall Street price target analysis for BTTAY.
MoonshotScore
What does this score mean?
The MoonshotScore rates BTTAY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Biotest AG ADR Information Unsponsored
Biotest AG (BTTAY) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BTTA
BTTAY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biotest Aktiengesellschaft may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history or those facing financial challenges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Potential for price volatility due to low trading volume.
- Higher risk of fraud or manipulation compared to major exchanges.
- Limited access to company information and management.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's debt levels and cash flow.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established operating history since 1946.
- Subsidiary of Grifols Biotest Holdings GmbH.
- Partnership with Grifols, S.A.
- Focus on specialized therapeutic areas with unmet medical needs.
Common Questions About BTTAY
What does Biotest Aktiengesellschaft do?
Biotest Aktiengesellschaft is a biopharmaceutical company that develops, manufactures, and sells biological and biotechnological pharmaceutical products. The company specializes in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its product portfolio includes therapies for haemophilia, cytomegalovirus infection, hepatitis B, antibody deficiency syndromes, autoimmune diseases, and bacterial infections. Biotest operates internationally and has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of certain products.
What do analysts say about BTTAY stock?
AI analysis is currently pending for BTTAY. Key valuation metrics to consider include the company's market capitalization of $1.60 billion, negative profit margin of -3.9%, and high debt-to-equity ratio of 131.22. Growth considerations include the potential for increased revenue through the Grifols partnership and expansion of the product portfolio. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for BTTAY?
The main risks for Biotest Aktiengesellschaft include its negative profit margin and ROE, high debt-to-equity ratio, intense competition from major pharmaceutical companies, stringent regulatory requirements, and limited liquidity due to its OTC market trading. The company's reliance on a limited number of key products also poses a risk, as generic erosion could impact revenue. Additionally, the OTC Other tier classification indicates a higher level of risk compared to companies listed on major exchanges.
What are the key factors to evaluate for BTTAY?
Biotest AG (BTTAY) currently holds an AI score of 48/100, indicating low score. Key strength: Specialized product portfolio in immunology and haematology.. Primary risk to monitor: Ongoing: Negative profit margin and ROE.. This is not financial advice.
How frequently does BTTAY data refresh on this page?
BTTAY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BTTAY's recent stock price performance?
Recent price movement in Biotest AG (BTTAY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio in immunology and haematology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BTTAY overvalued or undervalued right now?
Determining whether Biotest AG (BTTAY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BTTAY?
Before investing in Biotest AG (BTTAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or unreliable.
- AI analysis is pending and may provide further insights.